The Wayback Machine - https://web.archive.org/web/20171109082205/http://prosigna.com:80/x-us/overview/prosigna-algorithm/
Home
US Residents
This site is intended for non-US residents only.
UPDATES
May 26, 2016
Cigna Issues Positive Coverage Decision for NanoString’s Prosigna® Breast Cancer Assay
May 9, 2016
Aetna Issues Positive Coverage Decision for NanoString’s Prosigna® Breast Cancer Assay
March 2016
NanoString Technologies Receives Favorable Final Local Coverage Determination by Noridian Healthcare Solutions for Its Prosigna Breast Cancer Assay
February 2016
American Society of Clinical Oncology (ASCO) Clinical Practice Guideline Recommends Use of Prosigna (PAM50) for Guiding Treatment Decisions in Early Stage Breast Cancer Patients
Show Archive

Use Prosigna to predict your patient’s Risk of Recurrence (ROR)*

Prosigna generates ROR from a proprietary algorithm1

  • Intrinsic subtypes are biologically and clinically distinct types of breast cancer that are characterized by different PAM50 gene expression signatures2,3
  • ROR is derived from a proprietary algorithm based on the PAM50 gene signature, intrinsic subtype, tumor size, nodal status, and proliferation score1
  • The gene expression profile of a patient’s tumor is compared to each of the defined intrinsic subtype gene signatures to determine the degree of similarity1
  • Proliferation score is determined by evaluating multiple genes within the proliferation pathway4
  • ROR is provided as a numerical score on a 0-to-100 scale that estimates the probability of distant recurrence over 10 years1
Risk of Recurrence (ROR) algorithm compares patient gene expression profile to intrinsic subtypes

*ROR score is Prosigna’s proprietary model for predicting risk of recurrence in a patient. Probability of recurrence cannot be guaranteed.



References: 1. Prosigna [Package Insert]. Seattle, WA: NanoString Technologies, Inc; 2013. 2. Parker JS, Mullins M, Cheang MC, et al. Supervised risk predictor of breast cancer based on intrinsic subtypes. J Clin Oncol. 2009;27(8):1160-1167. 3. Perou CM, Sørlie T, Eisen MB, et al. Molecular portraits of human breast tumours. Nature. 2000;406(6797):747-752. 4. Bastien RRL, Ebbert MTW, Boucher KM, et al. Using the PAM50 breast cancer intrinsic classifier to assess risk in ER+ breast cancers: a direct comparison to Oncotype DX. Presented at: 47th American Society of Clinical Oncology Annual Meeting; June 3-7, 2011; Chicago, IL. Abstract 503. 5. Nielsen T, McDonald S, Kulkarni S, et al. Analytical reproducibility of the breast cancer intrinsic subtyping test and nCounter® Analysis System using formalin-fixed paraffin-embedded (FFPE) breast tumor specimens. Poster presented at: 102nd United States and Canadian Academy of Pathology Annual Meeting; March 2-8, 2013; Baltimore, MD. Abstract 2075. 6. Gnant M, Filipits M, Mlineritsch B, et al; Austrian Breast and Colorectal Cancer Study Group. Clinical validation of the PAM50 risk of recurrence (ROR) score for predicting residual risk of distant-recurrence (DR) after endocrine therapy in postmenopausal women with HR+ early breast cancer (EBC): an ABCSG study. Presented at: San Antonio Breast Cancer Symposium; December 4-8, 2012; San Antonio, TX. Abstract P2-10-02.

Prosigna is indicated for use in postmenopausal women with hormone receptor-positive, node-negative or node-positive early-stage (stages I, II and IIIA) breast cancer to be treated with adjuvant endocrine therapy.

© 2014-15 NanoString Technologies, Inc. All rights reserved. NanoString, the NanoString Technologies logo, nCounter, Prosigna and the Prosigna logo are trademarks and/or registered trademarks of NanoString Technologies, Inc. in various jurisdictions.
Contact Us | Contact Support | Sitemap | Legal | Terms of Sale | 1-206-378-6266